The difference in time to healing between patients receiving foscarnet or placebo was not significant. Fewer patients treated with foscarnet had positive viral cultures after treatment, but the difference was not significant. The development of new lesions, however, was significantly less common in patients given foscarnet. Though topical foscarnet is a safe drug, no appreciable efficacy in treating recurrent genital HSV infection could be shown.
Introduction
The herpes simplex viruses (HSV) are among the most common human pathogens. Their characteristic feature is a capacity to establish latency in the host after the initial infection and to reactivate periodically.
Genital herpes is most commonly due to HSV type 2.' Though this disease has been recognised for hundreds of years,2 with many attempts at treatment, the past 10 On admission to the study, patients had evidence of a recurrence in the prodromal, erythematous, papular, or vesicular stage. Patients with vesicles were included only if they were seen within six hours of detection of the lesions.
Patients were excluded if they had had a previous genital HSV recurrence, had received antiviral treatment within the preceding two weeks, had had immunostimulant treatment within the previous month, had had antiherpes immunotherapy within the past 12 months, or if they were immunodeficient. Furthermore, patients with other concomitant genital infection requiring treatment and patients with a history of allergy to any of the constituents of the cream (such as parabenes) were also excluded, as were pregnant and breast feeding women.
At the initial visit, patients to be included in the trial gave their written informed consent to participating in the study. At each clinic visit the genital area and the original lesion were examined and swabbed for viral HSV culture. The assessment ofthe original lesion was based on the following variables: area of erythema, stage of lesion (redness, swelling, blisters, sores, or S E Barton, et al Patients were randomly allocated either foscarnet cream (03% for men and 1% for women) or placebo (the vehicle only) in identically labelled 5 g tubes. Each tube was labelled with the patient's number. Treatment started immediately, and the patient was instructed about continuing treatment at home and about recording on a form details of symptoms, signs, and treatment. Treatment was administered every two hours on day 1, and then every four hours on days 2 to 5. The cream was applied topically in sufficient quantity to cover the lesion completely.
No concomitant antiviral treatment was permitted. If other drugs were taken they were recorded by the investigator. The patients revisited the clinic for assessment on days 3 to 5 and again on days 7 to 9. If the original lesion was not healed by this third visit another appointment was made after the lesion had healed. At the first and last visit the patient had a blood test to measure routine haematological and biochemical variables. At each visit the patient was asked general and specific questions about adverse events and local intolerance.
Statistical analysis of the data used the KaplanMeier product limit estimator to assess the time event functions. In addition, the log rank test was used to test the hypothesis that two such functions for foscarnet and placebo were equal."`12 Conventional (two tailed) non-parametric statistical methods were used to analyse the remaining data.
Results
From March 1984 to April 1985, 253 patients (152 men, 101 women) entered the study. Seventeen patients did not fulfil the entry criteria; nine had extragenital lesions, four had had vesicles for more than six hours before treatment started, two had yeast infections, one was pregnant, and one was receiving steroid treatment. Four further patients did not return after the first visit and two had more than one lesion Topical treatment of recurrent genital HSV infections with foscarnet assessed: these were excluded from analysis. Data relating to the remaining 230 patients were valid for efficacy evaluation. Data for men and women were analysed separately.
MEN
Of the 145 assessable men, 71 received foscarnet and 74 placebo. The groups were similar with regard to age, concomitant disease, current medication, medical history, and previous positive genital HSV culture. There was no appreciable difference in the lesion stage, location, size, severity ofpain or itching, or virus isolation rate between the groups at the start of treatment. The duration and frequency of applications of cream did not differ between the two groups. The median time to healing (complete re-epithelialisation) of the original lesion was five days in both groups ( fig  1) . In the subgroup of patients with HSV culture positive lesions, however, the median time to healing was five days in those treated with foscarnet and six days in those receiving placebo (p=0 44). In a subgroup with small lesions at the start of treatment, the median time to healing was two days for foscamet compared to five days for placebo (p=0002), whereas in the subgroup with medium sized lesions at the start of treatment the median time to healing was shorter for placebo (four days) than for foscarnet (five days) (p=008).
The proportion of patients with a positive HSV culture from day 2 to healing was 26% in those receiving foscarnet and 43% in those receiving placebo (p=0O07). The significantly reduced by treatment with foscamet, except for pain in the group of patients with small lesions. In the same group, foscamet treatment reduced the mean number of days with sores.
Three (4%) of the 71 men receiving foscarnet and eight ( 1%) of the 74 receiving placebo reported local intolerance. Adverse events were reported by eight (11%) receiving foscamet and four (5%) receiving placebo.
WOMEN
Of the 85 assessable women, 44 received foscamet and 41 placebo: both groups were similar at the start of treatment and were similar in presentation of the lesion. The groups were similar regarding duration and frequency of treatment and the pattern of concomitant medication, including contraceptive practice. The median time to healing was four days in both groups (fig 2) . In women with positive HSV cultures at the start of treatment, the time to healing was five days in both groups (p=0 29). The proportion ofpatients with positiv-e HSV cultures after treatment was started was 15% (6/41) in those receiving foscarnet compared with 30% (12/41) in those receiving placebo (p=O 19). Three patients treated with foscarnet were not tested. No lesions treated with placebo aborted, whereas 7% of lesions treated with foscarnet aborted. All these lesions were small, however, and none was HSV culture positive. More patients receiving placebo developed new lesions (p=0 06) and the mean duration of sores was shorter than in patients receiving foscarnet (p=009) when only large lesions were considered.
Seven patients (16%) receiving foscamet and seven (17%) receiving placebo reported local intolerance.
Adverse events were reported by six (14%) of those receiving foscarnet and five (12%) receiving placebo. 
